Stoke Therapeutics (NASDAQ:STOK) Coverage Initiated at Chardan Capital

Research analysts at Chardan Capital began coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a report released on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $24.00 price target on the stock. Chardan Capital’s price objective would suggest a potential upside of 105.48% from the stock’s current price.

A number of other brokerages have also recently issued reports on STOK. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $11.68 on Friday. Stoke Therapeutics has a one year low of $4.09 and a one year high of $17.58. The business has a fifty day moving average price of $12.48 and a 200-day moving average price of $13.54. The firm has a market capitalization of $618.65 million, a price-to-earnings ratio of -5.56 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, equities research analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 13,945 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the sale, the insider now owns 47,332 shares in the company, valued at approximately $604,902.96. The trade was a 22.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the sale, the general counsel now directly owns 21,476 shares in the company, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 in the last quarter. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in STOK. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter worth approximately $29,000. Nisa Investment Advisors LLC lifted its position in Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Stoke Therapeutics during the second quarter worth $123,000. Intech Investment Management LLC bought a new position in Stoke Therapeutics during the third quarter valued at $160,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.